Citations with the tag: SCHIZOPHRENIA -- Treatment

Results 1 - 50

  • Balancing hope with safety.
    Folkenberg, Judy // FDA Consumer; Jun90, Vol. 24 Issue 5, p16 

    Reports how Clozaril, a new antipsychotic drug, can help thousands of the most seriously afflicted schizophrenics function well enough to leave mental hospitals. But it also can cause a serious blood disorder. INSET: A psychiatric mystery, by J.F..

  • Treatment resistance in schizophrenia.
    Johnston, Eve C.; Sandler, Robert // BMJ: British Medical Journal (International Edition); 2/10/96, Vol. 312 Issue 7027, p325 

    Focuses on the use of alternative drugs in treating schizophrenia. Functions of chlorpromazine; Use of functional imaging techniques in schizophrenia.

  • Cognitive improvement is possible for schizophrenic patients.
    Spaulding, William D. // Behavioral Health Treatment; Oct96, Vol. 1 Issue 4, p3 

    Asserts that cognitive improvement is possible for schizophrenic patients in the United States. Results of re-examination of old assumptions concerning schizophrenia; Clinical manifestations of the ailment; Advances in neuropsychology.

  • Early relapse may result from neuroleptic withdrawal.
    Spaulding, William D. // Behavioral Health Treatment; Jun97, Vol. 2 Issue 6, p5 

    States that persons with schizophrenia who are abruptly withdrawn from neuroleptics may be twice as likely to suffer relapses within six months. Information on the study which provided the evidence; Details on the findings of the study.

  • Fish oil may relieve schizophrenia symptoms.
    Spaulding, William D. // Behavioral Health Treatment; Oct97, Vol. 2 Issue 10, p3 

    Presents information on a study which examined ways to reduce the symptoms associated with schizophrenia. Information on fish oil and how it can be used as a treatment for certain schizophrenic symptoms; Identification of countries in which research is being carried out; Details on side effects...

  • Healing without hurting the troubled mind.
    Bradley, David // New Scientist; 9/12/92, Vol. 135 Issue 1838, p18 

    Reveals that a drug candidate that could treat the symptoms of schizophrenia without causing the debilitating side-effects of traditional drugs has been developed by chemists in the United States. Compound is named HP 236; Could replace the drug clozapine; Background of the disorder.

  • Schizophrenia.
    Paltak, Margie // FDA Consumer; Sep/Oct97, Vol. 31 Issue 6, p23 

    Scrutinizes schizophrenia, a mental illness. Causes and symptoms of schizophrenia; Characteristics of a schizophrenic; Development of antipsychotic medications and their side effects; Other treatment for schizophrenia.

  • APA practice guideline for the treatment of patients with...
    Rose, Verna L. // American Family Physician; 9/15/1997, Vol. 56 Issue 4, p1217 

    Provides guidelines for the treatment of patients with schizophrenia issued by the American Psychiatric Association (APA). Eight main sections of the guideline; List of conventional antipsychotic drugs in the guideline; Coverage and features of the guideline.

  • A new antipsychotic agent with dual benefits.
    Cerrato, Paul L. // RN; Feb98, Vol. 61 Issue 2, p71 

    Presents information on quetiapine (Seroquel) which was approved by the United States Food and Drug Administration for treating schizophrenia and other psychotic disorders. Side effects of the drug.

  • Clinical Manual for Treatment of Schizophrenia.
    Mairs, Hilary // Mental Health Practice; Mar2013, Vol. 16 Issue 6, p8 

    No abstract available.

  • Parliamentary group report calls for funding guarantees for schizophrenia care.
    Mairs, Hilary // British Journal of Hospital Medicine (17508460); Jun2011, Vol. 72 Issue 6, p310 

    The article discusses key recommendations of a report from the All Party Parliamentary Group on Mental Health which surveyed mental health trusts in England about the treatment of schizophrenia while highlighting the inconsistencies in the management of schizophrenia.

  • Drug treatment of schizophrenia.
    Walling, Anne D. // American Family Physician; 4/15/1998, Vol. 57 Issue 8, p1998 

    Presents the summary `Drug treatment of schizophrenia,' which can be found in The Practitioner dated January 1998.

  • Kayo chaos.
    Portyansky, Elena // Drug Topics; 10/20/97, Vol. 141 Issue 20, p32 

    Focuses on a drug called Seroquel (quetiapine fumarate), which was approved for the treatment of schizophrenia. Drug developed by Zeneca Pharmaceuticals; Efficacy and tolerability profile of the drug; Warning that quetiapine could result in the possible emergence of tardive dyskinesia.

  • Economic evaluations of olanzapine and risperidone.
    Shaw, James W. // American Journal of Health-System Pharmacy; 7/15/2002, Vol. 59 Issue 14, p1366 

    Presents an economic analysis comparing olanzapine and risperidone for treating schizophrenia. Overview of the disease; Costs of schizophrenia; Methods of economic evaluation; Results of randomized clinical trials.

  • Treating schizophrenia: New strategies.
    Williamson, John S.; Wyandt, Christy M. // Drug Topics; 11/6/2000, Vol. 144 Issue 21, p64 

    No abstract available.

  • Relapsing schizophrenic wants diazepam.
    Williamson, John S.; Wyandt, Christy M. // Pulse; 11/11/2002, Vol. 62 Issue 43, p32 

    Presents several treatment options from physicians for a relapsing schizophrenic patient in Great Britain. Emphasis on controlling patient's addiction to diazepam; Reintroduction of home treatment team to monitor the mental status of the patient; Use of diazepam as a bargaining tool to enhance...

  • Aripiprazole.
    Luisi, Andrea F. // Formulary; Nov2002, Vol. 37 Issue 11, p575 

    Discusses aripiprazole, an antipsychotic used for the treatment of schizophrenia. Mechanism of action; Pharmacology; Effectiveness; Pharmacokinetics. INSET: Formulary considerations.

  • Combined (Individual and Group) Psychodynamic Psychotherapy in the Rehabilitation of Schizophrenic Patients.
    Guseva, O.V.; Iovlev, B.V.; Shchelkova, O.Iu. // International Journal of Mental Health; Summer2002, Vol. 31 Issue 2, p61 

    Investigates the efficacy of combined psychodynamic psychotherapy in the rehabilitation of schizophrenic patients. Effectiveness of specific psychotherapy treatment; Selection of experimental-psychological methods adequate for the revelation of the dynamics of psychological parameters in...

  • Effectiveness of targeted intervention and maintenance pharmacotherapy in conjunction with family intervention in schizophrenia.
    Wiedemann, G.; Hahlweg, K.; Müller, U.; Feinstein, E.; Hank, G.; Dose, M. // European Archives of Psychiatry & Clinical Neuroscience; 2001, Vol. 251 Issue 2, p72 

    Abstract A sample of 85 patients with schizophrenia, of whom 34 later dropped out, received randomised treatment. There were no significant differences between treatment-takers and drop-outs in the variables assessed. Patients received either standard-dose maintenance neuroleptic treatment or...

  • A prospective 2-year follow-up study of neurocognitive functioning in patients with first-episode schizophrenia.
    Albus, Margot; Hubmann, Werner; Scherer, Josef; Dreikorn, Bettina; Hecht, Susanne; Sobizack, Norbert; Mohr, Fritz // European Archives of Psychiatry & Clinical Neuroscience; 2002, Vol. 252 Issue 6, p262 

    To investigate the temporal stability, or progressivity, of neuropsychological (NP) impairment in schizophrenia, 50 patients with first episode (FE) schizophrenia and 50 healthy controls were given a battery of tests at the outset of the study and after a two-year interval. Both patient and...

  • An Approach to the Understanding of 'Schizophrenese'
    Mosak, Harold H.; Maniacci, Michael P. // Individual Psychology: The Journal of Adlerian Theory, Research ; Dec89, Vol. 45 Issue 4, p465 

    Focuses on the conceptualization of schizophrenia disease. Symptoms of the disease; Guidelines for working psychotic populations; Importance of phenomenological perspective toward the treatment and understanding of schizophrenia.

  • Treatment alliance and the chronic schizophrenic.
    Selzer, Michael A.; Carsky, Monica // American Journal of Psychotherapy; Oct1990, Vol. 44 Issue 4, p506 

    Describes ways a psychotherapist can facilitate a sense of relatedness with the schizophrenic patient. Therapist's identification and joining with the part of the patient which is in conflict with his psychosis; Role of the techniques in allowing the patient to identify with and introject...

  • Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations.
    Llorca, Pierre-Michel; Lancon, Christophe; Disdier, Beatrice; Farisse, Jean; Sapin, Christophe; Auquier, Pascal // Journal of Psychiatry & Neuroscience; Jan2002, Vol. 27 Issue 1, p30 

    Evaluates the effectiveness of clozapine in neuroleptic-resistance schizophrenia, in terms of its clinical response and plasma concentrations. Mean endpoint clozapine dosage; Significant correlation found between the daily dosage of clozapine and the plasma levels of clozapine and of its...

  • Psychopharmacology for the Clinician.
    Prior, Trevor I. // Journal of Psychiatry & Neuroscience; May2002, Vol. 27 Issue 3, p224 

    Focuses on the pharmacologic management of patients with schizophrenia using clozapine. Side effects of clozapine; Role of cytochrome P450 enzymes in the mechanisms of side effects; Determination on the therapeutic serum levels of the drug.

  • Curtain on Schizophrenia: A Twenty-five-Year Clinical Follow-up.
    Betz, Barbara J. // American Journal of Psychotherapy; Apr1980, Vol. 34 Issue 2, p252 

    Reports on a 25-year clinical study of an individual patient's emergence from severe chronic schizophrenia. Demonstration of techniques to find ways around the basic schizophrenic instability; Description of the frame within which such a happening can follow.

  • Therapeutic Drug Monitoring: Chemical-Clinical Correlations of Atypical Antipsychotic Drugs.
    Raggi, M.A. // Current Medicinal Chemistry; Jul2002, Vol. 9 Issue 14, p1397 

    In the last few years, new drugs for the treatment of schizophrenia have been introduced in therapy which have noticeably improved the quality of life of many schizophrenic patients. These new �atypical� drugs have chemical, pharmacological and clinical properties which are different...

  • Letters to the Editor.
    Unger, Nathan; Addington, Donald // Canadian Journal of Psychiatry; Sep2012, Vol. 57 Issue 9, p583 

    A letter to the editor is presented in response to the article "Conformance to evidence-based treatment recommendations in schizophrenia treatment services," by Addington D, McKenzie E and Smith H which also includes a response by the author of the article.

  • Corrigenda: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
    Patil, Sandeep T; Zhang, Lu; Martenyi, Ferenc; Lowe, Stephen L; Jackson, Kimberley A; Andreev, Boris V; Avedisova, Alla S; Bardenstein, Leonid M; Gurovich, Issak Y; Morozova, Margarita A; Mosolov, Sergey N; Neznanov, Nikolai G; Reznik, Alexander M; Smulevich, Anatoly B; Tochilov, Vladimir A; Johnson, Bryan G; Monn, James A; Schoepp, Darryle D // Nature Medicine; Oct2007, Vol. 13 Issue 10, p1264 

    A correction to the article "Corrigenda: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial" that was published in the September, 2007 issue is presented.

  • Relatives and patients as partners in the management of...
    Birchwood, Max; Smith, Jo // Psychosocial Rehabilitation Journal; Jan90, Vol. 13 Issue 3, p27 

    Highlights the integration of family management of schizophrenia into clinical practice. Challenges faced by rehabilitation professionals involved in developing clinical services; Information on the problem of engagement; Description of the heavy demands on mental resources as a result of...

  • A large-scale field test of a medication management skills...
    Eckman, Thad A.; Liberman, Robert P. // Psychosocial Rehabilitation Journal; Jan90, Vol. 13 Issue 3, p31 

    Focuses on a field test study of the utility and efficacy of a medication program at the the University of California (UCLA) Clinical Research Center. Methods employed in study; Danger of failure to adhere to prescribed drugs, with reference to patients with chronic schizophrenic; Number of...

  • Review: limited evidence that adding a second antipsychotic improves clozapine treatment in schizophrenia.
    Eckman, Thad A.; Liberman, Robert P. // Evidence Based Mental Health; Nov2009, Vol. 12 Issue 4, p112 

    An abstract of the article "Review: limited evidence that adding a second antipsychotic improves clozapine treatment in schizophrenia," by C. Barbui and colleagues is presented.

  • Anxiogenic, not psychotogenic, properties of the partial inverse benzodiazepine receptor agonist FG 7142 in man.
    Horowski, R.; Dorow, R. // Psychopharmacology; 2002, Vol. 162 Issue 2, p223 

    Proposes the application of FG 7142, the first benzodiazepine receptor partial inverse agonist, as an alternative psychotogenic manipulation for studying cortical and cognitive aspects of schizophrenia. Side effects of the FG 7142; Description of patients on the experience using the substance;...

  • Rehabilitation & Schizophrenia: A Developmental Approach.
    McKenna, Patrick J. // Journal of Rehabilitation; Jul-Sep85, Vol. 51 Issue 3 

    Presents a discussion on the developmental rehabilitative approach for the treatment of schizophrenia in the United States. Reduction of functional deficits through the use of therapeutic activity; Emphasis on the approach on the intrapsychic maturation; Stages of treatment.

  • What works in schizophrenia.
    Haddad, Peter M.; Niaz, Omair // BMJ: British Medical Journal (International Edition); 8/12/2006, Vol. 333 Issue 7563, p353 

    This article presents a letter to the editor in response to the article, "Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study," by J. Tiihonen,...

  • Cognitive behaviour therapy is not effective.
    McKenna, Peter J. // BMJ: British Medical Journal (International Edition); 8/12/2006, Vol. 333 Issue 7563, p353 

    This article presents a letter to the editor in response to the article, "Psychological and social interventions for schizophrenia," by C. Kingdon in the July 29, 2006 issue.

  • Psychotherapy with command hallucinations in chronic schizophrenia: The use of action techniques...
    Honig, Albert M. // Journal of Group Psychotherapy, Psychodrama & Sociometry; Spring91, Vol. 44 Issue 1, p3 

    Presents action psychotherapeutic techniques, using the principles of psychodrama, that take a strong oppositional position to command hallucinations in chronic schizophrenia. Concept of the command auditory hallucinations; Implementation of action techniques within the surrogate family setting;...

  • Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia.
    Duncan, G.E.; Zorn, S.; Lieberman, J.A. // Molecular Psychiatry; 1999, Vol. 4 Issue 5, p418 

    Available evidence indicates that clozapine is the most effective antipsychotic currently used for the pharmacotherapy of schizophrenia. Unfortunately, clozapine can cause serious side effects that limit the use of the drug. The therapeutic mechanism of action of clozapine is poorly understood,...

  • Treating the untreatable: healing in the realms of madness.
    Traynor, Wendy // Healthcare Counselling & Psychotherapy Journal; Oct2010, Vol. 10 Issue 4, p46 

    The article reviews the book "Treating the Untreatable: Healing in the Realms of Madness," by Ira Steinman.

  • Medication Treatment Patterns following Initiation on Olanzapine versus Risperidone: A Retrospective Analysis.
    Zhao, Z.; Tunis, S.L.; Lage, M.J. // Clinical Drug Investigation; 2002, Vol. 22 Issue 11, p741 

    Objective: To compare medication treatment patterns for patients with schizophrenia following initiation on olanzapine versus risperidone. Methods: Retrospective analysis of a large, geographically diverse claims database of insured individuals identified 670 enrollees who: (1) were diagnosed...

  • Perospirone: A Viewpoint by Mitsukuni Murasaki.
    Murasaki, M. // CNS Drugs; 2001, Vol. 15 Issue 4, p338 

    Focuses on the use of the drug perospirone for treating schizophrenia. Disadvantages of the traditional antipsychotic drugs; Reasons for the development of perospirone; Difference from other drugs.

  • Perospirone.
    Onrust, S.V.; McClellan, K. // CNS Drugs; 2001, Vol. 15 Issue 4, p329 

    â–´ Perospirone is an atypical antipsychotic agent for the treatment of schizophrenia. Its primary mode of action is through antagonism of serotonin 5-HT and dopamine D receptors. â–´ An 8-week course of oral perospirone 8 to 48 mg/day displayed efficacy in up to 75% of patients with...

  • Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
    Kelleher, J.P.; Centorrino, F.; Albert, M.J.; Baldessarini, R.J.; Kelleher, James P; Centorrino, Franca; Albert, Matthew J; Baldessarini, Ross J // CNS Drugs; 2002, Vol. 16 Issue 4, p249 

    Innovation in atypical antipsychotic agents continues with new preparations of available drugs as well as novel agents. In this article, we provide an update on these novel products by reviewing information from a computerised literature search, recent abstracts and discussions with industry...

  • Symptomatic suppression.
    Hewitt, Allison // Pharmaceutical Executive; Dec97, Vol. 17 Issue 12, p88 

    Reports the effect of the Pfizer drug ziprasidone on patients with schizophrenia. Association of the drugs with decreased probability of relapse.

    Gibson, Alan C. // British Journal of Psychiatry; Jan78, Vol. 132, p111 

    A letter to the editor is presented about the means to treat schizophrenia.

  • Content and quality of 2000 controlled trials in schizophrenia over 50 years.
    Thornley, Ben; Adams, Clive // BMJ: British Medical Journal (International Edition); 10/31/98, Vol. 317 Issue 7167, p1181 

    Presents a survey which deals with content and quality of intervention studies relevant to the treatment of schizophrenia. Methodology; Results of the survey; Conclusions.

  • Conventional versus novel antipsychotics: changing concepts and clinical implications.
    Remington, Gary; Chong, Siow-Ann // Journal of Psychiatry & Neuroscience; Nov99, Vol. 24 Issue 5, p431 

    Compares the efficacy between novel and conventional antipsychotic drugs in treating schizophrenia. Implication of clozapine and other novel antipsychotics for neurotransmitter activity; Side effects of conventional antipsychotics; Effects of novel drugs on schizophrenic pharmacotherapy.

  • Refractory symptomatic schizophrenia resulting from frontal lobe lesion: response to clozapine.
    Burke, John G.; Dursun, Serdar M.; Reveley, Michael A. // Journal of Psychiatry & Neuroscience; Nov99, Vol. 24 Issue 5, p456 

    Examines the efficacy of clozapine in treating refractory symptomatic schizophrenia. Case study of a patient with frontal lobe lesion exhibiting psychotic tendencies; Role of brain language area dysfunctions in generating auditory hallucinations; Clinical response and action mechanism of clozapine.

  • Controlling acute and chronic schizophrenia.
    Rodman, Morton J. // RN; Apr78, Vol. 41 Issue 4, p75 

    Deals with drugs for controlling the manifestations of acute and chronic schizophrenia. Phenothiazine; Thioridazine.

  • Localization of dopamine D4 receptors in GABAergic neurons of the primate brain.
    Mrzljak, L.; Bergson, C. // Nature; 5/16/1996, Vol. 381 Issue 6579, p245 

    Reports on the production of a subtype-specific antibody against the D4 dopamine receptor subtype, which are the principal targets of drugs used in the treatment of schizophrenia. High D4 affinity for the atypical neuroleptic clozapine; Localization of the receptor within specific cellular...

  • Nutritional Approaches.
    Butlin, June // Positive Health; Jan2003, Issue 84, p36 

    Focuses on the orthomolecular approach using a combination of vitamins, minerals, amino acids and essential fatty acids in treating schizophrenia. Importance of continued research for the complicated illness and a combination of mainstream medicine and nutrition and other complementary therapies.

Next 50 Results
That might join me putting you to

Other Topics